Twitter Facebook LinkedIn YouTube

Trulieve Cannabis Corp. (CSE:TRUL) New Listing

Video Platform Video Management Video Solutions Video Player

Trulieve US is the first and largest fully-licensed medical cannabis company in the state of Florida and serves over 80,000 patients. It is completely vertically integrated with over 450,000 square feet of cultivation facilities with a further 95,000 square feet to be added in 2018.

Additional Information:

Company: Trulieve Cannabis Corp
Website: http://www.trulieve.com
Stock Symbol: CSE: TRUL
Transcript: Available

Video Transcript:

I’m Megan Edwards for Investmentpitch Media

Trulieve Cannabis Corp.is the latest new listing on the Canadian Securities Exchange, trading under the symbol “TRULI”, following a RTO with Schyan Exploration Inc., a reporting issuer in the Province of Ontario.

Trulieve US is the first and largest fully-licensed medical cannabis company in the state of Florida and serves over 80,000 patients.

It is completely vertically integrated with over 450,000 square feet of cultivation facilities with a further 95,000 square feet to be added in 2018.

The company operates a certified processing facility that produces 90 different private label, medical grade cannabis products that are sold through 17 company-owned dispensaries.

Kim Rivers, CEO, stated: “Trulieve US was built with a patients-first mentality by focusing on improving access to medical cannabis while producing the highest quality products in the industry. Achieving this important milestone of a public listing enhances our ability to expand and serve more patients while allowing investors to participate in our growth.”

The company recently released its financials for the quarter ending June 30, 2018.

The company ended the quarter with 16 operating dispensaries serving 83,000 active patients.

Revenue grew from US$15.2 million in the quarter ended March 31, 2018 to US$23.3 million for the quarter ended June 30, 2018.

EBITDA increased from US$11.2 million in the quarter ended March 31, 2018 to US$14.3 million for the quarter ended June 30, 2018.

Kim Rivers, CEO, further commented: “The second quarter of 2018 demonstrated our ability to scale our business profitably with growth in dispensaries and patients served driving growth in revenue and EBITDA. This momentum is continuing in the current quarter and we expect strong results throughout 2018.”

The shares are currently trading at $11.75.

For more information, please visit the company’s website at www.trulieve.com, contact Kevin Darmody, Director of Investor Relations, at 850-480-7955 or email IR@trulieve.com.

I’m Megan Edwards for Investmentpitch Media